Replimune Group, Inc. (REPL) Earnings
Replimune Group, Inc. is expected to report next earnings on June 5, 2026 (in NaN days), with a consensus EPS estimate of $-0.73. REPL has beaten EPS estimates in 6 of its last 12 reported quarters (average surprise -4.5% over the last four).
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Feb 3, 2026 | $-0.85 | $-0.77 | +9.4% | — | — |
| Nov 6, 2025 | $-0.87 | $-0.90 | -3.4% | — | — |
| Aug 7, 2025 | $-0.83 | $-0.95 | -14.5% | — | — |
| May 22, 2025 | $-0.75 | $-0.82 | -9.3% | $1M | — |
| Feb 12, 2025 | $-0.70 | $-0.79 | -12.9% | — | — |
| Aug 8, 2024 | $-0.88 | $-0.78 | +11.4% | — | — |
| May 16, 2024 | $-0.86 | $-0.82 | +4.7% | $4M | — |
| Feb 8, 2024 | $-0.94 | $-0.77 | +18.1% | — | — |
| Aug 3, 2023 | $-0.85 | $-0.75 | +11.8% | — | — |
| May 18, 2023 | $-0.66 | $-0.74 | -12.1% | — | — |
| Feb 9, 2023 | $-0.77 | $-0.69 | +10.4% | — | — |
| Nov 3, 2022 | $-0.78 | $-0.79 | -1.3% | — | — |
Source: company filings + earnings calendar. For informational purposes only — not investment advice.
Earnings call summary
Q4 FY2025 · May 22, 2025
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
Sushil Patel began by highlighting the progress in regulatory, clinical, and commercial aspects for RP1, including RP1 being a breakthrough therapy with a PDUFA date of July 22, 2025, and the Ignite 3 confirmatory study underway. Chris Sarchi discussed launch preparation, including commercial organization build-out, focus on oncologists and interventional radiologists collaboration, and procedural codes and reimbursement support. Emily Hill provided financial updates, noting cash and cash equivalents of $483.8M as of March 31, 2025, R&D expenses of $54M for Q4 2025, SG&A expenses of $25.4M for Q4 2025, and a net loss of $74.1M for Q4 2025. The company also plans an Investor Day on June 24 to discuss various aspects including the melanoma landscape and pipeline development.
Guidance
Existing cash, cash equivalents, and short-term investments as of March 31, 2025, are expected to fund operations into Q4 2026. The Ignite 3 confirmatory trial enrollment in the U.S. is on track. The company anticipates broad and rapid adoption of RP1 post-approval, with focus on U.S. enrollment for the Ignite 3 trial. An Investor Day is scheduled for June 24 to share insights on the melanoma landscape, RP1 roadmap, and pipeline.
Risks & headwinds
Changes in market conditions and difficulties associated with research and development, and regulatory approval processes. These and other risk factors are described in the filings made with the SEC.
Analyst Q&A
Q: With the PDUFA around the corner, what sort of medical education work are you going to be doing at ASCO ahead of the launch of RP1?
A: Sushil Patel mentioned sharing data on response rates for different lesion types, biomarker biodistribution, and safety, including data on systemic and visceral activity and RP1 neutralization by routine disinfectants.
Q: Given the dynamic for the launch between the oncologists and interventional radiologists, can you just give us some color around your expectations for the launch trajectory?
A: Chris Sarchi stated anticipation of broad and rapid adoption across hospitals and communities, with around 150 top accounts trained by launch, and over 90% of those spoken to willing to utilize RP1 upon approval.
Q: What is the impact you're seeing from the recent regulatory changes and provide any color on recent FDA interactions?
A: Emily Hill and Sushil Patel discussed FDA engagement, completion of late-cycle meeting and manufacturing inspections, and being on track for the July 22 PDUFA with no impediments.
Q: Can you discuss the confirmatory IGNITE3 trial experience and label strategy?
A: Sushil Patel talked about enrollment progress in the U.S. for Ignite 3, focusing on avoiding control arm enrollment post-PDUFA, and expectation of a broad label reflecting the study population from IGNYTE.
Q: Ahead of the potential commercial launch, can you maybe talk a little bit about how you're planning for manufacturing resiliency and cost of goods?
A: Sushil Patel mentioned in-house manufacturing at a U.S. facility, off-the-shelf product for next-day use, attractive cost of goods due to early investment in manufacturing, and capacity for long-term global demand.
Q: Any of the gating factors that exist between now and due to date, especially around CMC? And thoughts on revenue guidance?
A: Sushil Patel noted completion of CMC-related meetings and inspections, and Emily Hill stated revenue guidance will be provided later, focusing on patient numbers and payers post-launch